Muscular Dystrophy Trial, Recruiting NCT05019625 Sponsor: Massachusetts General Hospital Condition: Muscular Dystrophy
Back to Muscular Dystrophy

Muscular Dystrophy Trial, Recruiting

NCT05019625
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who have been diagnosed with Myotonic Dystrophy Type 1 (DM1) or Type 2 (DM2) through genetic testing and/or clinical features, including those who have tested positive but have no symptoms, or those with characteristic features who have not had genetic testing done.
  • People with no known muscular dystrophy who may be eligible to participate as a comparison (control) group.
  • People who are able to give written consent or assent to take part in the study.
  • For a single fluid sample collection: males and females aged 5 years and older.
  • For repeated fluid samples and muscle function testing: males and females aged 14 years and older with DM1.
  • For fluid samples and a muscle biopsy: males and females aged 18 to 65 years.
  • For a single fluid sample collection combined with ultrasound and muscle response testing: males and females aged 14 years and older.

Who may not be able to join:

  • People with a medical history of a weakened immune system, a blood clotting disorder, pre-existing liver or kidney disease, a documented positive HIV diagnosis, or documented hepatitis B and/or C.
  • People who have taken anti-platelet medications (blood-thinning drugs that affect platelets) within the 7 days before a blood draw or biopsy.
  • People who have taken anticoagulant medications (blood-thinning drugs) within the 60 days before a blood draw or biopsy.
  • People with active drug or alcohol use or dependence that, in the opinion of the biopsy surgeon, could interfere with care after a biopsy procedure.
  • People who are unwilling or unable to provide written informed consent.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Thurman M. Wheeler, MD, Massachusetts General Hospital

Phone: 617-726-7506

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Registry
ClinicalTrials.gov
Start date
20 February 2015
Est. completion
1 June 2027

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Extracellular RNA in biofluids

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov